source
- BD and CareFusion recall Alaris Pump infusion sets due to serious performance risksThe FDA has classified the recall of BD Alaris Pump infusion sets as the most serious type, warning that continued use could cause serious injury or death. BD and its subsidiary CareFusion sent an…
- Biomea posts modest Phase 1 results for oral GLP-1 drug, shares slideBiomea Fusion released Phase 1 data for its oral small‑molecule GLP‑1 agonist BMF‑650, positioning the program as a potential partner opportunity that could separate efficacy from gastrointestinal…